Myriad Genetics, Inc. MYGN recently announced updates to its agreement with Illumina Inc. ILMN. The company’s gold-standard Genomic Instability Score (“GIS”) to determine Homologous Recombination ...

Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Eisbach Bio's innovative approach focuses on exploiting the unique genetic vulnerabilities present in solid tumors with deficiencies in certain DNA repair pathways. Eisbach's proprietary ALLOS ...

Screening for pancreatic cancer is recommended for individuals with the above risk factors around 50 years of age or 10 years ...

Illumina currently has a market capitalization of $20.74 billion. The company’s earnings in 2024 are expected to surge nearly 343% compared to the industry’s 17.8% growth. In the trailing four ...

a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination ...

Pancreatic cancer, specifically pancreatic adenocarcinoma, remains one of the most aggressive and deadliest cancers worldwide ...

SOPHiA GENETICS launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024: Boston, Massachusetts Saturday, November 23, 2024, 16:00 Hrs [IST] SOPHiA GENETICS, a cloud-native healthc ...

Olaparib monotherapy may be a treatment option for some patients with high-risk biochemically recurrent prostate cancer, according to researchers.

Department of Molecular Biology, Kyushu University Graduate School of Pharmaceutical Sciences, Fukuoka, Japan ...

After hours: November 25 at 5:47 PM EST Loading Chart for IDYA ...

Illumina to release new version of its flagship cancer research assay, TruSight Oncology 500 v2: San Diego Thursday, November 21, 2024, 16:00 Hrs [IST] Illumina, Inc., a global le ...